Regulatory & Reimbursement
FDA Output, October 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in October 2026. Updated October 7.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Investors & Dealmaking
MedTech Capital Matters September 2026
Recent private financings of medtech companies. The summer was by no means sleepy, with at least 22 venture capital deals.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Investors & Dealmaking
Despite AI’s Allure, Medtech Investors Stay Grounded
Medtech investing has maintained its momentum from 2025 through 2026, according to PwC’s latest medtech deals outlook. Excerpted from our recent feature, “As Dollars Chase AI Dream, Investors Stay Grounded.”